ClinicalTrials.gg
CompletedNCT02344849Updated Jan 9, 2019

Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction

A Phase 1 interventional study of mesenchymal stem cell in Erectile Dysfunction, sponsored by Pharmicell Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Pharmicell Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Erectile Dysfunction with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Erectile Dysfunction · Korea, Republic of.

Enrollment
25th of 25
10 · median 104
Started
2015
with 1 other
Phase 1
7 of 31
none open now
Registered
21st of 31
by date
Lead sponsor
4 of 31
Pharmicell Co., Ltd.

Among the 31 studies in Erectile Dysfunction with a site in Korea, Republic of, this one is the 25th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2015, is one of 7 in phase 1, and was the 21st registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

3 of the 31 studies in Erectile Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Erectile Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Read the detailed description

Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days. Ten patients (Diabetes -associated ED; 5 patients, Postprostatectomy; 5patients) will be injected Cellgram-ED directly into the intracavernous. Patient will be evaluated the safety and potential efficacy of MSC.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Postprostatectomy Erectile Dysfunction

  • A man aged 20 or older
  • Who is willing to consent to participate in the study concerned with improving sexual activity after prostatectomy, the man has maintained normal sexual activity prior to prostatectomy
  • Prior to prostatectomy PSA (prostate specific antigen) level\<10 ng/mL
  • At the time of Prostatectomy, Pathological Gleason sum ≤7
  • At the time of Prostatectomy, Pathological stage ≤ T2c
  • 2 years or more postprostatectomy patients with PSA level ≤ 0.04 ng/mL without additional therapy after prostatectomy
  • Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.
  • IIEF, EF(erectile function) domain score is under 17
  • Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.

Diabetes-associated Erectile Dysfunction

  • is between 6.5% and 10% of man over 20 years of age with diabetes
  • Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I within last 8weeks.
  • IIEF, EF domain score is under 17
  • Who is willing to consent to participate in the study concerned with improving sexual activity
  • Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.

Exclusion criteria

Exclusion Criteria:

  • History of bone marrow disorders
  • Serum /ALT > 3 X or Creatinine > 1.5 X upper limit of normal
  • History of against a gentamycin
  • Severe cardiovascular disease(angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure
  • Positive for (HIV), virus (HBV), virus (HCV) and syphilis test
  • Positive for PSA or CEA or AFP (Carcinoembryonic antigen), history of cancer in the last five years (except Prostatic cancer) Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or \< 90 mm Hg, diastolic pressure > 100 or \< 50 mm Hg)
  • exhibit greater than 10%
  • Men on anticoagulant treatment
  • Have a severe infectious disease
  • Testosterone level is less than 200ng/dl
  • Have a penile implant or willing to it
  • Patients with morphological changes of the penis
  • Patient's partner is trying to conceive during the trial period
  • Unwilling to participate in the study
  • Participating in other clinical trials in the past 30 days
  • Unable to compliance with protocol
  • Inappropriate patients to participate in the study according to the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Mesenchymal stem cell

    Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.

    Drug: mesenchymal stem cell

Interventions

  • Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.

    Also known as: Cellgram-ED

06

What researchers measure

Primary outcomes

  1. Number and severity of adverse events

    Analyze the laboratory, vital sign, physical exam results from baseline to end of the study for investigate adverse reactions and view safety. An SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that: Results in death. Is life-threatening.\* Requires in-patient hospitalization or prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Other medically important condition Life-threatening in the definition of a SAE or adverse reaction refers to an event in which the patient was at risk of death at the time of event; it does not refer to an event, which hypothetically might have caused death if it were more severe.

    Time frame: 12month

Secondary outcomes

  1. Change From Baseline in the International Index of Erectile Function(IIEF)

    Description of the average variation from the screening value in each group using the Student's preordered t-test (Wilcoxon's signed bank test). Function domain * Erectile Function (Q1,2,3,4,5,15) : Min 6 \~ Max 30 * Orgasmic Function (Q9,10) : Min 2 \~ Max 10 * Sexual Desire (Q11,12) : : Min 2 \~ Max 10 * Intercourse Satisfaction (Q6,7,8): : Min 3 \~ Max 15 * Overall Satisfaction (Q13,14) : Min 2 \~ Max 10

    Time frame: month 1, 3, 6, 9 and 12

  2. Penile Doppler Sonography, PDS

    Change From Baseline in Peak systolic velocity (PSV) and End diastolic velocity (EDV), Evaluate Erection rigidity During the test. The normal maximum systolic blood flow of the cavernosal artery after injection of vasodilators is 30 cm / s or more. 1. PDS results are obtained 5 min, 10 min, 15 min, 20 min, 25 min and 30 min after intracavernosal injection. 2. The peak systolic velocity (PSV) is assessed as follows: \>25 cm/s is considered to be normal, 20-25 cm/s is considered to be mild ED, 12-20 cm/s is considered to be moderate ED, \<12 cm/s is considered to be severe arteriogenic impotence. 3. The end diastolic velocity (EDV) is assessed as follows: * 5 cm/s is considered to be a normal value, \>5 cm/s is considered to indicate a veno-occlusive disorder.

    Time frame: month 6, 12

  3. Change From Baseline in Sexual Encounter Profile (SEP) Question 2

    The SEP2 survey describes cumulative success rates for 30 days, 3 months, 6 months, 9 months and 12 months after cell treatment. SEP 2 Were you able to insert your penis into your partner's vagina? Yes or No SEP 3 Did your erection last long enough to have successful intercourse? Yes or No

    Time frame: month 1, 3, 6, 9 and 12

  4. Global Assessment Question (GAQ)

    The GAQ survey describes cumulative success rates for 30 days, 3 months, 6 months, 9 months and 12 months after cell treatment. GAQ 1. Did Cellgram-ED improve your Erectile Function? Yes or No 2. If so, did Cellgram-ED improve the ability to have sex? Yes or No

    Time frame: month 1, 3, 6, 9 and 12

07

Study locations

1 site
  • Asan medical center
    Seoul, Korea, Republic of
08

References and documents

Publications

  • You D, Jang MJ, Song G, Shin HC, Suh N, Kim YM, Ahn TY, Kim CS. Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. Cytotherapy. 2021 Oct;23(10):931-938. doi: 10.1016/j.jcyt.2021.06.001. Epub 2021 Jul 27. PubMed 34326007 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jan 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2015
First posted
Jan 26, 2015
Start
Jul 2015
Primary completionActual
Jan 31, 2018
CompletionActual
Apr 2018
Last update
Jan 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02344849
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Jan 26, 2015
Start date
Jul 2015
Primary completion
Jan 31, 2018
Completion
Apr 2018
Last update
Jan 9, 2019

Study contacts

Chungsu Kim, Ph.D
principal investigator · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion